IRLAB THERAPEUTICS AB SER. A revenue breakdown overview

IRLAB THERAPEUTICS AB SER. A revenue for the last year amounted to 57.05 M SEK, the most of which — 94.63 M SEK — came from its highest performing source at the moment, Mesdopetam, Pirepemate and Integrative Screening Process, the year earlier bringing 5.68 M SEK. The greatest contribution to the revenue figure was made by United States — last year it brought IRLAB THERAPEUTICS AB SER. A 94.63 M SEK, and the year before that — 4.22 M SEK.